Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Biogenerics standoff

Nature Biotechnology volume 22, pages 1343–1346 (2004)Cite this article

Healthcare costs are out of control. Generic biotech products could ease the pain. What's holding things up? Stephan Herrera investigates.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. SMI out of pocket expenses as percentage of illustrative Social Security benefit. http://www.house.gov/stark/news/108th/news_2004-09-14_MedPremDoc.htm

  2. Garsten, D. GM health care bill tops $60 billion. Detroit News March 11 (2004), p. 1. http://www.detnews.com/2004/autosinsider/0403/11/a01-88813.htm

    Google Scholar 

  3. Hakim, D. Carmakers in for a long haul in paying for retiree health care. New York Times September 14 (2004), p. 1.

    Google Scholar 

  4. Henry, J. Kaiser Family Foundation. Trends and indicators in the changing health care marketplace, 2004 Update. April 2004.

  5. Louët, S. Lessons from Eprex for biogeneric firms, Nat. Biotech. 21, 956–957 (2003).

    Article  CAS  Google Scholar 

  6. Abboud, L. How drug giant keeps monopoly on 60-year old pill. Wall Street Journal September 9 (2004), p. A1.

  7. Turner, N. Biogenerics, a difficult birth? IMS Health, Online newsletter, May 18, 2004. http://open.imshealth.com/webshop2/IMSinclude/i_article_20040518a.asp

  8. USFDA/CDER Report to the Nation: 1999, International Activities. (FDA/Center for Drug Evaluation and Research, Washington, DC, 2001). http://www.fda.gov/cder/reports/rtn99-4.htm

Download references

Author information

Authors and Affiliations

  1. New York

    Stephan Herrera

Authors
  1. Stephan Herrera
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Betting on biogenerics

Biomanufacturing, from bust to boom...to bubble?

Profile: Thomas Lönngren

Related external links

BIO's position on biogenerics

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herrera, S. Biogenerics standoff. Nat Biotechnol 22, 1343–1346 (2004). https://doi.org/10.1038/nbt1104-1343

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1104-1343

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing